MedPath

Prophylaxis Against Tuberculosis (TB) in Patients With Human Immunodeficiency Virus (HIV) Infection and Confirmed Latent Tuberculous Infection

Not Applicable
Completed
Conditions
HIV Infections
Tuberculosis
Registration Number
NCT00000636
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Brief Summary

To evaluate and compare the effectiveness of a 2-month regimen of rifampin and pyrazinamide versus a 1-year course of isoniazid (INH) to prevent the development of tuberculosis in patients who are coinfected with HIV and latent Mycobacterium tuberculosis (MTb).

Current guidelines recommend 6 to 12 months of treatment with INH for purified protein derivative (PPD)-positive individuals. Problems with this treatment include compliance, adverse reaction, and the possibility of not preventing disease due to INH-resistant organisms. Studies suggest that two or three months of rifampin and pyrazinamide may be more effective than longer courses of INH. A two-month prevention course should help to increase compliance. In addition, the use of two drugs (rifampin and pyrazinamide) may help overcome problems with drug resistance.

Detailed Description

Current guidelines recommend 6 to 12 months of treatment with INH for purified protein derivative (PPD)-positive individuals. Problems with this treatment include compliance, adverse reaction, and the possibility of not preventing disease due to INH-resistant organisms. Studies suggest that two or three months of rifampin and pyrazinamide may be more effective than longer courses of INH. A two-month prevention course should help to increase compliance. In addition, the use of two drugs (rifampin and pyrazinamide) may help overcome problems with drug resistance.

After baseline screening, patients are randomized to one of two treatment arms and are evaluated by means of clinic visits monthly for the first three months, then every three months for the first year (there are additional clinic visits for INH patients). Patients are then evaluated every six months. One group of patients takes INH plus vitamin B6 for 12 months. The other group of patients takes 1 of 2 doses of rifampin (depending on patient's weight) plus pyrazinamide in 3-4 divided doses for 60 days.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
2000
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (25)

AIDS Research Consortium of Atlanta

🇺🇸

Atlanta, Georgia, United States

Philadelphia FIGHT

🇺🇸

Philadelphia, Pennsylvania, United States

Boston Dept of Health and Hosps

🇺🇸

Boston, Massachusetts, United States

Chicago Dept of Health / Speciality STD Clinic

🇺🇸

Chicago, Illinois, United States

Wilmington Hosp / Med Ctr of Delaware

🇺🇸

Wilmington, Delaware, United States

Southern New Jersey AIDS Cln Trials / Dept of Med

🇺🇸

Camden, New Jersey, United States

AIDS Research Alliance - Chicago

🇺🇸

Chicago, Illinois, United States

Addiction Research and Treatment Corp

🇺🇸

Brooklyn, New York, United States

Johns Hopkins Univ / Brazil

🇺🇸

Baltimore, Maryland, United States

Saint Michael's Med Ctr

🇺🇸

Newark, New Jersey, United States

Clinical Directors Network of Region II

🇺🇸

New York, New York, United States

Beth Israel Med Ctr

🇺🇸

New York, New York, United States

Lattimore Comprehensive Pulmonary Disease Clinic

🇺🇸

Newark, New Jersey, United States

Community Consortium / UCSF

🇺🇸

San Francisco, California, United States

Johns Hopkins Univ / School of Hygiene & Public Health

🇺🇸

Baltimore, Maryland, United States

Veterans Administration Med Ctr / Regional AIDS Program

🇺🇸

Washington, District of Columbia, United States

Harlem AIDS Treatment Group / Harlem Hosp Ctr

🇺🇸

New York, New York, United States

North Jersey Community Research Initiative

🇺🇸

Newark, New Jersey, United States

Denver CPCRA / Denver Public Hlth

🇺🇸

Denver, Colorado, United States

Hill Health Corp

🇺🇸

New Haven, Connecticut, United States

Louisiana Comm AIDS Rsch Prog / Tulane Univ Med

🇺🇸

New Orleans, Louisiana, United States

Comprehensive AIDS Alliance of Detroit

🇺🇸

Detroit, Michigan, United States

Henry Ford Hosp

🇺🇸

Detroit, Michigan, United States

Bronx Lebanon Hosp Ctr

🇺🇸

Bronx, New York, United States

Richmond AIDS Consortium

🇺🇸

Richmond, Virginia, United States

© Copyright 2025. All Rights Reserved by MedPath